Reducing Glucagon Secretion: GLP-1 inhibits the secretion of glucagon, a hormone that increases blood sugar levels by promoting the release of glucose from the liver
Int Immunopharmacol
A Pfizer spokesperson did not immediately respond to a request for comment on pricing and a China launch date
Oliver Sum-Ping, MD, a Clinical Associate Professor of Psychiatry and Sleep Medicine at Stanford Medicine who wasnt affiliated with the research told Healthline, The results suggest substantial potential for the role of these medications for at least mitigating OSA. The SURMOUNT-OSA trial was a multi-center, randomized, double-blind, placebo-controlled trial conducted with 469 patients, all of whom had OSA
SREBP-1c, sterol regulatory element binding protein-1c
Some studies have explored daily GLP1 medications, but they use specially formulated versions designed for daily use not just splitting up a weekly pen